

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended **September 30, 2017**

Commission File Number: **000-55596**

MyDx, Inc.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of
incorporation or organization)

99-0384160

(I.R.S. Employer
Identification No.)

6335 Ferris Square, Suite B

San Diego, CA 92121

(Address of principal executive offices) (Zip Code)

(800) 814-4550

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/> (Do not check if a smaller reporting company)	Smaller reporting company	<input checked="" type="checkbox"/>
		Emerging growth company	<input checked="" type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No .

Number of shares of common stock outstanding as of November 13, 2017 was 1,809,028,964.

TABLE OF CONTENTS

	<u>Page</u>
PART I - FINANCIAL INFORMATION	
Item 1. Condensed Consolidated Financial Statements	1
Condensed Consolidated Balance Sheets as of September 30, 2017 (Unaudited) and December 31, 2016	1
Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2017 and 2016 (unaudited)	2
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2017 and 2016 (unaudited)	3
Notes to Condensed Consolidated Financial Statements	4
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	26
Item 3. Quantitative and Qualitative Disclosures about Market Risk	32
Item 4. Controls and Procedures	33
PART II - OTHER INFORMATION	
Item 1. Legal Proceedings	34
Item 1A. Risk Factors	34
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	34
Item 3. Defaults Upon Senior Securities	35
Item 4. Mine Safety	35
Item 5. Other Information	35
Item 6. Exhibits	35
Signatures	36
Exhibit Index	

PART I - FINANCIAL INFORMATION

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

MyDx, Inc.
Condensed Consolidated Balance Sheets
(unaudited)

	<u>September 30,</u> <u>2017</u>	<u>December 31,</u> <u>2016</u>
ASSETS		
Current assets:		
Cash	\$ 162,451	\$ 38,203
Accounts receivable	27,851	27,851
Inventory	165,999	155,233
Prepaid expenses and other current assets	46,101	79,965
Total current assets	402,402	301,252
Property and equipment, net	82,800	138,883
Other assets	42,345	49,845
Total assets	\$ 527,547	\$ 489,980
LIABILITIES AND STOCKHOLDERS' DEFICIT		
Current liabilities:		
Asset based loans	\$ -	\$ 120,460
Accounts payable	1,169,916	1,082,384
Customer deposits	33,032	16,767
Accrued liabilities	143,497	131,563
Current portion of leases payable	2,756	3,480
Due to related party	76,075	1,075
Convertible notes payable, current, net of debt discount	-	233,147
Derivative liability	833,742	1,812,441
Warrant liability	-	247,203
Total current liabilities	2,259,018	3,648,520
Convertible note payable - related party	-	200,000
Notes payable, net of debt discount and debt issuance costs	465,295	-
Total liabilities	2,724,313	3,848,520
Commitments and contingencies (Note 11)		
Stockholders' deficit:		
Series A Preferred stock, \$0.001 par value; 51 and 51 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively	-	-
Series B Preferred stock, \$0.001 par value; 300,000 and 300,000 shares issued and outstanding as of September 30, 2017 and and December 31, 2016, respectively	300	300
Common stock, \$0.001 par value, 10,000,000,000 shares authorized; 1,726,528,964 and 645,060,704 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively	1,726,529	645,061
Additional paid-in capital	25,000,731	22,395,552
Accumulated deficit	(28,924,326)	(26,399,453)
Total stockholders' deficit	(2,196,766)	(3,358,540)
Total liabilities and stockholders' deficit	\$ 527,547	\$ 489,980

See notes to consolidated financial statements

MYDX INC.
Condensed Consolidated Statements of Operations
(unaudited)

	<u>For the Three Months Ended</u> <u>September 30,</u>		<u>For the Nine Months Ended</u> <u>September 30,</u>	
	<u>2017</u>	<u>2016</u>	<u>2017</u>	<u>2016</u>
Sales				
Product revenue	\$ 104,650	\$ 134,240	\$ 315,851	\$ 506,880
Royalty revenue	-	-	-	-
Licensing revenue	4,315	-	4,315	68,000
Total sales	<u>108,965</u>	<u>134,240</u>	<u>320,166</u>	<u>574,880</u>
Cost of goods sold				
Product costs	32,941	79,434	93,976	285,123
Total cost of sales	<u>32,941</u>	<u>79,434</u>	<u>93,976</u>	<u>285,123</u>
Gross profit	<u>76,024</u>	<u>54,806</u>	<u>226,190</u>	<u>289,757</u>
Operating Expenses				
Research and development	39,595	111,315	87,602	352,407
Sales and marketing	68,420	1,588,884	741,813	1,792,496
General and administrative	175,936	276,182	1,040,550	1,416,440
Total operating expenses	<u>283,951</u>	<u>1,976,381</u>	<u>1,869,965</u>	<u>3,561,343</u>
Loss from operations	<u>(207,927)</u>	<u>(1,921,575)</u>	<u>(1,643,775)</u>	<u>(3,271,586)</u>
Other income (expense)				
Interest expense, net	(47,234)	(807,621)	(330,522)	(863,001)
Change in fair value of derivative liability	(3,759)	198,338	116,083	198,338
Derivative expense	(133,489)	-	(999,920)	-
Gain (loss) on settlement of debt	-	(335,952)	198,261	(409,887)
Gain on forfeiture of technology transfer deposit	-	-	135,000	-
Income (loss) before provision for income taxes	<u>(392,409)</u>	<u>(2,866,810)</u>	<u>(2,524,873)</u>	<u>(4,346,136)</u>
Provision for income taxes	-	-	-	1,850
Net income (loss)	<u>\$ (392,409)</u>	<u>\$ (2,866,810)</u>	<u>\$ (2,524,873)</u>	<u>\$ (4,347,986)</u>
Income (loss) per share				
Basic and diluted	<u>\$ (0.00)</u>	<u>\$ (0.08)</u>	<u>\$ (0.00)</u>	<u>\$ (0.15)</u>
Weighted average common shares outstanding - basic and diluted	<u>1,669,527,890</u>	<u>34,235,772</u>	<u>1,456,764,275</u>	<u>29,750,062</u>

See notes to consolidated financial statements

MyDx, INC.
Condensed Consolidated Statements of Cash Flows

	Nine Months Ended September 30,	
	2017	2016
Cash flows from operating activities:		
Net loss	\$ (2,524,873)	\$ (4,347,986)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	57,878	59,422
Impairment of assets	-	13,126
Common stock issued in exchange for services	473,800	304,237
Change in fair value of derivative liability	(116,083)	-
Interest expense related to debt issuance costs	999,920	182,211
Gain on changes in fair value of derivative liability	(44,005)	(198,338)
Loss on settlement of debt	-	409,982
Gain on settlement of vendor liabilities	(154,255)	-
Stock based compensation	247,420	377,669
Interest expense related to amortization of debt issuance costs and debt discount	275,407	549,000
Changes in assets and liabilities:		
Accounts receivable	-	(29,695)
Inventory	(10,766)	110,451
Prepaid expenses and other assets	41,365	34,251
Accounts payable and accrued liabilities	399,360	1,770,342
Customer deposits	-	68,852
Long term obligations	16,265	-
Current portion leases payable	(724)	142
Long-term portion of leases payable	-	(2,213)
Net cash used in operating activities	(339,291)	(698,547)
Cash flows from financing activities		
Proceeds from the issuance of common stock	245,500	-
Proceeds from note payable - related party	165,000	25,000
Repayment of related party loans	(90,000)	-
Proceeds from note payable, net of debt discount and issuance costs	263,500	-
Proceeds from the issuance of convertible notes payable, net of issuance costs	-	490,122
Proceeds from issuance of asset based loans, net of issuance costs	-	300,000
Repayments on asset based loans	(120,461)	(76,503)
Net cash provided by financing activities	463,539	738,619
Net increase	124,248	40,072
Cash, beginning of period	38,203	143,680
Cash, end of period	\$ 162,451	\$ 183,752
Supplemental cash flow information:		
Interest paid	\$ 13,755	\$ 40,547
Taxes paid	\$ -	-
Supplemental disclosure of non-cash investing and financing activities:		
Settlement of debt with convertible note	\$ 655,955	\$ -
Derivative cease to exist upon conversion of notes	\$ 1,783,475	\$ -
Debt discount recorded on convertible debt	\$ -	\$ -
Conversion of convertible notes payable to preferred stock	\$ -	\$ 826,367

See notes to consolidated financial statements

MyDx, INC.
Notes to Condensed Consolidated Financial Statements
(unaudited)

1. Organization

MyDx, Inc. (the “Company”, “we”, “us” or “our”) (formally known as Brista Corp.) was incorporated under the laws of the State of Nevada on December 20, 2012. The Company’s wholly-owned subsidiary, CDx, Inc., was incorporated under the laws of the State of Delaware on September 16, 2013.

2. Nature of Business

MyDx is a science and technology company that develops and deploys products and services in the following focus areas:

- 1) **Consumer Products** – smart devices and consumables
- 2) **Data Analytics** – pre-clinical chemical analysis and patient feedback ecosystem
- 3) **Biopharmaceuticals** – identifying ‘green Active Pharmaceutical IngredientsTM, (gAPITM) and corresponding formulations
- 4) **Software as a Service (SaaS)** – Software services for prescribers, patient groups, cultivators, and regulators

We are committed to addressing areas of critical national need to promote public safety, transparency and regulation in the various markets we serve.

The Company’s first product, MyDx[®], also known as “My Diagnostic”, is a patented multiuse hand-held chemical analyzer made for consumers and professional users which feeds our data analytics platform and SaaS business. MyDx is intended to allow consumers to Trust & Verify[®] what they put into their mind and body by using our science and technology to test for pesticides in food, chemicals in water, toxins in the air, and the safety and potency of cannabis samples, which is our initial focus.

3. Going Concern

The Company has adopted ASU No. 2014-15, “*Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern* (“ASU 2014-15”).

The Company’s condensed consolidated financial statements have been prepared assuming it will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business.

As reflected in the condensed consolidated Financial Statements, the Company had an accumulated deficit at September 30, 2017, and a net loss for the nine months ended September 30, 2017. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

The Company is attempting to further implement its business plan and generate sufficient revenues; however, its cash position may not be sufficient to support its daily operations. The Company has a limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by early-stage companies. These risks include, but are not limited to, the uncertainty of availability of financing and the uncertainty of achieving future profitability. Management anticipates that the Company will be dependent, for the near future, on investment capital to fund operating expenses. The Company intends to position itself so that it may be able to raise funds through the capital markets. There can be no assurance that such financing will be available at terms acceptable to the Company, if at all. Failure to generate sufficient cash flows from operations, raise capital or reduce certain discretionary spending could have a material adverse effect on the Company's ability to achieve its intended business objectives. We reported negative cash flow from operations for the nine months ended September 30, 2017 and 2016. It is anticipated that we will continue to report negative operating cash flow in future periods, likely until one or more of our products generates sufficient revenue to cover our operating expenses. If any of the warrants are exercised, all net proceeds of the warrant exercise will be used for working capital to fund negative operating cash flow.

Our cash balance of \$162,451 at September 30, 2017 will not be sufficient to fund our operations for the next 12 months. Additionally, if we are unable to generate sufficient revenues to pay our expenses, we will need to raise additional funds to continue our operations. We have historically financed our operations through private equity and debt financings. We do not have any commitments for financing at this time, and financing may not be available to us on favorable terms, if at all. If we are unable to obtain debt or equity financing in amounts sufficient to fund our operations, if necessary, we will be forced to suspend or curtail our operations. In that event, current stockholders would likely experience a loss of most or all of their investment. Additional funding that we do obtain may be dilutive to the interests of existing stockholders.

The condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

4. Summary of Significant Accounting Policies

Basis of Presentation

These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting and include the accounts of the Company and its wholly owned subsidiary. Certain information and note disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company's Form 10-K filed with the SEC on April 20, 2017, as amended on April 26, 2017.

The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, necessary for the fair presentation of the Company's statement of financial position as of September 30, 2017 and the Company's results of operations for the three and nine months ended September 30, 2017 and 2016 and its cash flows for the nine months ended September 30, 2017 and 2016. The results for the nine months ended September 30, 2017 are not necessarily indicative of the results to be expected for the year ending December 31, 2017. All references to September 30, 2017 or to the three and nine months ended September 30, 2017 and 2016 in the notes to condensed consolidated financial statements are unaudited.

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting period. Such management estimates include allowance for doubtful accounts, estimates of product returns, warranty expense, inventory valuation, valuation allowances of deferred taxes, stock-based compensation expenses and fair value of warrants. The Company bases its estimates on historical experience and on assumptions that it believes are reasonable. The Company assesses these estimates on a regular basis; however, actual results could materially differ from those estimates.

Concentration of Risk Related to Third-party Suppliers

We depend on a limited number of third-party suppliers for the materials and components required to manufacture our products. A delay or interruption by our suppliers may harm our business, results of operations, and financial condition, and could also adversely affect our future profit margins. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must change or add new suppliers. Our dependence on our suppliers exposes us to numerous risks, including but not limited to the following: our suppliers may cease or reduce production or deliveries, raise prices, or renegotiate terms; we may be unable to locate a suitable replacement supplier on acceptable terms or on a timely basis, or at all; and delays caused by supply issues may harm our reputation, frustrate our customers, and cause them to turn to our competitors for future needs.

Fair Value of Financial Instruments

The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). Each level of input has different levels of subjectivity and difficulty involved in determining fair value.

- Level 1 Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurable date.
- Level 2 Inputs, other than quoted prices included in Level 1, that are observable for the asset or liability through corroboration with market data at the measurement date.
- Level 3 Unobservable inputs that reflect management's best estimate of what participants would use in pricing the asset or liability at the measurement date.

The carrying amounts of the Company's financial assets and liabilities, including cash, accounts receivable, accounts payable, and accrued liabilities approximate fair value because of the short maturity of these instruments. The carrying value of the Company's loan payable and convertible notes payable approximates fair value based upon borrowing rates currently available to the Company for loans with similar terms.

Cash

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of September 30, 2017, and December 31, 2016, the Company held no cash equivalents.

The Company's policy is to place its cash with high credit quality financial instruments and institutions and limit the amounts invested with any one financial institution or in any type of instrument. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company makes ongoing assumptions relating to the collectability of its accounts receivable in its calculation of the allowance for doubtful accounts. In determining the amount of the allowance, the Company makes judgments about the creditworthiness of customers based on ongoing credit evaluations and assesses current economic trends affecting its customers that might impact the level of credit losses in the future and result in different rates of bad debts than previously seen. The Company also considers its historical level of credit losses. As of September 30, 2017 and 2016, there was no allowance for doubtful accounts.

Inventory

Inventory is stated at the lower of cost or market value. Inventory is determined to be salable based on demand forecast within a specific time horizon, generally eighteen months or less. Inventory in excess of salable amounts and inventory which is considered obsolete based upon changes in existing technology is written off. At the point of recognition, a new lower cost basis for that inventory is established and subsequent changes in facts and circumstances do not result in the restoration or increase in that new cost basis.

Property and Equipment

Property and equipment are recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided using the straight-line method over the useful life as follows:

Internal-use software	3 years
Equipment	3 to 5 years
Computer equipment	3 to 7 years
Furniture and fixtures	5 to 7 years
Leasehold improvements	Shorter of life of asset or lease

Accounting for Website Development Costs

The Company capitalizes certain external and internal costs, including internal payroll costs, incurred in connection with the development of its website. These costs are capitalized beginning when the Company has entered the application development stage and cease when the project is substantially complete and is ready for its intended use. The website development costs are amortized using the straight-line method over the estimated useful life of three years.

Impairment of Long-Lived Assets

Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the condensed balance sheets and reported at the lower of the carrying amount or fair value less costs to sell, and no longer depreciated. The assets and liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability sections of the condensed balance sheets.

Debt Discount and Debt Issuance Costs

Debt discounts and debt issuance costs incurred in connection with the issuance of debt are capitalized and amortized to interest expense based on the related debt agreements using the straight-line method. Unamortized discounts are netted against long-term debt.

Derivative Liability

In accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Paragraph 815-15-25-1 the conversion feature and certain other features are considered embedded derivative instruments, such as a conversion reset provision, a penalty provision and redemption option, which are to be recorded at their fair value as its fair value can be separated from the convertible note and its conversion is independent of the underlying note value. The Company records the resulting discount on debt related to the conversion features at initial transaction and amortizes the discount using the effective interest rate method over the life of the debt instruments. The conversion liability is then marked to market each reporting period with the resulting gains or losses shown in the statements of operations.

In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.

The Company follows ASC Section 815-40-15 ("Section 815-40-15") to determine whether an instrument (or an embedded feature) is indexed to the Company's own stock. Section 815-40-15 provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument's contingent exercise and settlement provisions. The adoption of Section 815-40-15 has affected the accounting for (i) certain freestanding warrants that contain exercise price adjustment features and (ii) convertible bonds issued by foreign subsidiaries with a strike price denominated in a foreign currency.

The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with paragraph 810-10-05-4 and Section 815-40-25 of the FASB Accounting Standards Codification. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as either an asset or a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the consolidated statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation and then that the related fair value is reclassified to equity.

The Company utilizes the Black-Scholes option-pricing model to compute the fair value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The Black-Scholes option-pricing model includes subjective input assumptions that can materially affect the fair value estimates. The expected volatility is estimated based on the most recent historical period of time equal to the remaining contractual term of the instrument granted.

Income Taxes

Income taxes are provided in accordance with ASC No. 740, "*Accounting for Income Taxes*". A deferred tax asset or liability is recorded for all temporary differences between financial and tax reporting and net operating loss carry forwards. Deferred tax expense (benefit) results from the net change during the period of deferred tax assets and liabilities.

Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

The Company is no longer subject to tax examinations by tax authorities for years prior to 2013.

Revenue Recognition

The Company recognizes revenue from product sales upon shipment as long as evidence of an arrangement exists, the fee is fixed or determinable, collection of the resulting receivable is reasonably assured and title and risk of loss have passed. If those criteria are not met, then revenue will not be recognized until all of the criteria are satisfied.

Product Returns

For any product in its original, undamaged and unmarked condition, with its included accessories and packaging along with the original receipt (or gift receipt) within 30 days of the date the customer receives the product, the Company will exchange it or offer a refund based upon the original payment method.

Customer Deposits

The Company accounts for funds received from crowdfunding campaigns and pre-sales as a liability on the consolidated balance sheets as the investments made entitle the investor to apply these funds towards future shipments once the product has been developed and available for commercial use.

Research and Development Costs

Research and development costs are charged to expense as incurred. These costs consist primarily of salaries and direct payroll-related costs. It also includes purchased materials and services provided by independent contractors, software developed by other companies and incorporated into or used in the development of our final products. Research and development expenses for the three months ended September 30, 2017 and 2016 were \$39,595 and \$111,315, respectively. Research and development expenses for the nine months ended September 30, 2017 and 2016 were \$87,602 and \$352,407, respectively.

Advertising Costs

Advertising costs are charged to sales and marketing expenses and general and administrative expenses as incurred. Advertising expenses, which are recorded in sales and marketing and general and administrative expenses, totaled \$80,874 and \$276,183 for the three months ended September 30, 2017 and 2016, respectively. Advertising expenses totaled \$754,267 and \$1,416,440 for the nine months ended September 30, 2017 and 2016, respectively.

Stock-Based Compensation

The Company accounts for stock-based compensation in accordance with ASC Topic 718, “*Compensation – Stock Compensation*” (“ASC 718”) which establishes financial accounting and reporting standards for stock-based employee compensation. It defines a fair value based method of accounting for an employee stock option or similar equity instrument. Accordingly, stock-based compensation is recognized in the consolidated statements of operations as an operating expense over the requisite service period. The Company uses the Black-Scholes option pricing model adjusted for the estimated forfeiture rate for the respective grant to determine the estimated fair value of stock-based compensation arrangements on the date of grant and expenses this value ratably over the requisite service period of the stock option. The Black-Scholes option pricing model requires the input of highly subjective assumptions. Because the Company’s stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models may not provide a reliable single measure of the fair value of the Company’s stock options. In addition, management will continue to assess the assumptions and methodologies used to calculate estimated fair value of stock-based compensation. Circumstances may change and additional data may become available over time, which could result in changes to these assumptions and methodologies for future grants, and which could materially impact the Company’s fair value determination.

The Company accounts for share-based payments to non-employees in accordance with ASC 505-50 “*Equity Based Payments to Non-Employees*”. If the equity instrument is a stock option, the Company uses the Black-Scholes option pricing model to determine the fair value. Assumptions used to value the equity instruments are consistent with equity instruments issued to employees as the terms of the awards are similar. The Company recognizes the fair value of the equity instruments as expense over the term of the service agreement and revalues that fair value at each reporting period over the vesting periods of the equity instruments.

Warranty

The Company provides a limited warranty for its analyzers and sensors for a period of 1 year from the date of shipment that such goods will be free from material defects in material and workmanship. The Company has assessed the historical claims and, to date, warranty claims have not been significant. The Company will continue to assess the need to record a warranty accrual at the time of sale going forward.

Collaborative Arrangements

The Company and its collaborative partners are active participants in the collaborative arrangements and both parties are exposed to significant risks and rewards depending on the commercial success of the activity. The Company records all expenses related to collaborative arrangements as research and development expense in the consolidated statements of operations as incurred.

Net Loss per Share

Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, which is the case for the three months ended September 30, 2017 and 2016 presented in these condensed consolidated financial statements, the weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive.

The Company had the following common stock equivalents at September 30, 2017 and 2016:

	September 30, 2017	September 30, 2016
Convertible accounts payable	273,860,683	-
Options	1,490,000	4,123,186
Warrants	260,345,149	7,571,395
Totals	<u>535,695,832</u>	<u>11,694,581</u>

Subsequent events

The Company has evaluated events that occurred subsequent to September 30, 2017 and through the date the financial statements were issued.

Reclassifications

Certain prior year amounts in the condensed consolidated financial statements and the notes thereto have been reclassified where necessary to conform to the current year presentation. These reclassifications did not affect the prior period total assets, total liabilities, stockholders' deficit, net loss or net cash used in operating activities.

Recently Adopted Accounting Guidance

In May 2014, the FASB issued a comprehensive new revenue recognition standard that will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The standard's core principle (issued as ASU 2014-09 by the FASB), is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The new guidance must be adopted using either a full retrospective approach for all periods presented in the period of adoption or a modified retrospective approach. In August 2015, the FASB issued ASU No. 2015-14, which defers the effective date of ASU 2014-09 by one year, and would allow entities the option to early adopt the new revenue standard as of the original effective date. This ASU is effective for public reporting companies for interim and annual periods beginning after December 15, 2016. The standard permits the use of either the retrospective or cumulative effect transition method. The adoption of ASU 2014-15 did not materially impact our consolidated financial position, results of operations or cash flows.

In August 2014, the FASB issued ASU 2014-15, "Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern." ASU 2014-15 provides guidance on management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company's ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in ASU 2014-15 are effective for annual reporting periods ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company has elected to adopt the methodologies prescribed by ASU 2014-15. The adoption of ASU 2014-15 had no material effect on its financial position or results of operations.

In March 2015, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) No. 2015-03, “Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The amendments are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption of the amendments is permitted for financial statements that have not been previously issued. The amendments should be applied on a retrospective basis, wherein the balance sheet of each individual period presented should be adjusted to reflect the period-specific effects of applying the new guidance. Upon transition, an entity is required to comply with the applicable disclosures for a change in an accounting principle. These disclosures include the nature of and reason for the change in accounting principle, the transition method, a description of the prior-period information that has been retrospectively adjusted, and the effect of the change on the financial statement line items (i.e., debt issuance cost asset and the debt liability). The Company adopted ASU 2015-03 during the year ended December 31, 2016. The adoption of ASU 2015-03 had no material effect on its financial position or results of operations or cash flows.

In July 2015, the FASB issued ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory”, which modifies existing requirements regarding measuring inventory at the lower of cost or market. Under current inventory standards, the market value requires consideration of replacement cost, net realizable value and net realizable value less an approximately normal profit margin. The new guidance replaces market with net realizable value defined as estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This eliminates the need to determine and consider replacement cost or net realizable value less an approximately normal profit margin when measuring inventory. The standard is required to be adopted for annual periods beginning after December 15, 2016, including interim periods within that annual period, which is our fiscal year 2018. The amendment is to be applied prospectively with early adoption permitted. The adoption of ASU 2015-11 had no material effect on its financial position or results of operations or cash flows.

In April 2016, the FASB issued ASU No. 2016-09, “Compensation – Stock Compensation” (topic 718). The FASB issued this update to improve the accounting for employee share-based payments and affect all organizations that issue share-based payment awards to their employees. Several aspects of the accounting for share-based payment award transactions are simplified, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The updated guidance is effective for annual periods beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption of the update is permitted. The adoption of ASU 2016-09 had no material effect on its financial position or results of operations or cash flows.

In May 2016, the FASB issued ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients”, which narrowly amended the revenue recognition guidance regarding collectability, noncash consideration, presentation of sales tax and transition and is effective during the same period as ASU 2014-09. The adoption of ASU 2016-12 had no material effect on its financial position or results of operations or cash flows.

Recent Accounting Guidance Not Yet Adopted

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842).” Under ASU 2016-02, lessees will be required to recognize, for all leases of 12 months or more, a liability to make lease payments and a right-of-use asset representing the right to use the underlying asset for the lease term. Additionally, the guidance requires improved disclosures to help users of financial statements better understand the nature of an entity’s leasing activities. This ASU is effective for public reporting companies for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and must be adopted using a modified retrospective approach. The Company is in the process of evaluating the effect of the new guidance on its condensed consolidated financial statements and disclosures.

In April 2016, the FASB issued ASU No. 2016-10, “*Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing*” (topic 606). In March 2016, the FASB issued ASU No. 2016-08, “*Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross versus Net)*” (topic 606). These amendments provide additional clarification and implementation guidance on the previously issued ASU 2014-09, “*Revenue from Contracts with Customers*”. The amendments in ASU 2016-10 provide clarifying guidance on materiality of performance obligations; evaluating distinct performance obligations; treatment of shipping and handling costs; and determining whether an entity’s promise to grant a license provides a customer with either a right to use an entity’s intellectual property or a right to access an entity’s intellectual property. The amendments in ASU 2016-08 clarify how an entity should identify the specified good or service for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements. The adoption of ASU 2016-10 and ASU 2016-08 is to coincide with an entity’s adoption of ASU 2014-09, which we intend to adopt for interim and annual reporting periods beginning after December 15, 2017. The Company is currently evaluating the impact of the new standard.

In August 2016, the FASB issued ASU 2016-15, “*Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments*” (“ASU 2016-15”). ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017. The new standard will require adoption on a retrospective basis unless it is impracticable to apply, in which case it would be required to apply the amendments prospectively as of the earliest date practicable. The Company is currently in the process of evaluating the impact of ASU 2016-15 on its condensed consolidated financial statements.

In October 2016, the FASB issued ASU 2016-16, “*Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory*”, which eliminates the exception that prohibits the recognition of current and deferred income tax effects for intra-entity transfers of assets other than inventory until the asset has been sold to an outside party. The updated guidance is effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption of the update is permitted. The Company is currently evaluating the impact of the new standard.

In November 2016, the FASB issued ASU 2016-18, “*Statement of Cash Flows (Topic 230)*”, requiring that the statement of cash flows explain the change in the total cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. This guidance is effective for fiscal years, and interim reporting periods therein, beginning after December 15, 2017 with early adoption permitted. The provisions of this guidance are to be applied using a retrospective approach which requires application of the guidance for all periods presented. The Company is currently evaluating the impact of the new standard.

Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying condensed consolidated financial statements.

5. Inventory

Inventory as of September 30, 2017, and December 31, 2016 is as follows:

	September 30, 2017	December 31, 2016
Finished goods	\$ 98,129	\$ 3,033
Raw materials	67,870	152,200
	<u>\$ 165,999</u>	<u>\$ 155,233</u>

6. Property and Equipment, net

	September 30, 2017	December 31, 2016
Computer and test equipment	\$ 198,684	\$ 198,684
Website development costs	39,870	39,870
Furniture and fixtures	26,948	26,948
Software	10,791	10,791
Leasehold improvements	18,288	18,288
	294,581	294,581
Accumulated depreciation and amortization	(211,781)	(155,698)
	<u>\$ 82,800</u>	<u>\$ 138,883</u>

Depreciation expense was \$17,764 and \$16,730 for the three months ended September 30, 2017 and 2016, respectively. Depreciation expense was \$57,878 and \$59,422 for the nine months ended September 30, 2017 and 2016, respectively.

For the nine months ended September 30, 2016 the Company recorded an impairment of assets totaling \$13,127 for assets that the Company no longer uses.

Accrued Liabilities

Accrued liabilities consisted of the following as of September 30, 2017 and December 31, 2016.

	September 30, 2017	December 31, 2016
Accrued compensation for employees	\$ 51,861	\$ 71,351
Deferred compensation to non-employee	15,423	45,086
Accrued interest on notes payable	45,475	9,727
Other payables	30,738	5,399
	<u>\$ 143,497</u>	<u>\$ 131,563</u>

8. Debt

Asset Based Loans

On September 16, 2016, CDx, Inc. (the Company's wholly owned subsidiary) entered into a Business Loan Agreement (the "Agreement") with WebBank providing for the granting of a security interest in properties, assets and rights (the "Collateral") as defined in the agreement. CDx, Inc. received net proceeds of \$150,000. There were no loan origination or administrative fees related to the funding. The agreement has a maturity date that is 432 days after the effective date of the Agreement and requires equal weekly payments of \$599 which includes a total finance fee of \$34,500 over the life of the Agreement. The Agreement is personally guaranteed by an officer and majority shareholder of the Company. The outstanding balance at September 30, 2017 was \$0.

On May 31, 2016, CDx, Inc. (the Company's wholly owned subsidiary) entered into a Promissory Note and Security Agreement (the "Note") with Windset Capital Corporation, whereby CDx, Inc. gives, grants and assigns a continuing security interest in all of CDx, Inc.'s business equipment, accounts receivable, intellectual property, rights, licenses, claims, assets and properties of any kind whatsoever, whether now owned or hereafter acquired, real, personal, tangible, intangible or of any nature or value, wherever located, together with all proceeds including insurance proceeds as defined in the Note. There was an origination fee of \$200 related to the financing. CDx, Inc. received net proceeds of \$74,800 from the funding. The Note has a maturity date that is 252 business days from the date of the Note and requires payments of \$360 each business day, as defined in the Note, which includes a total finance fee of \$15,750 over the life of the Note. The Note is personally guaranteed by an officer and majority shareholder of the Company. The outstanding balance at September 30, 2017 was \$0.

On May 31, 2016, CDx, Inc. (the Company's wholly owned subsidiary) entered into a Future Receivables Sale Agreement (the "Agreement") with Swift Financial Corporation granting a security interest, as defined in the Agreement, in CDx, Inc.'s present and future accounts, receivables, chattel paper, deposit accounts, personal property, goods, assets and fixtures, general intangibles, instruments, equipment and inventory. There was an origination fee of \$1,875 related to the financing. CDx, Inc. received net proceeds of \$73,125 from the funding. The Agreement requires 48 equal weekly payments of \$1,842 resulting in total repayment of \$88,425 which includes a finance fee of \$13,425. The total repayment amount can be reduced to \$85,425 solely in the event CDx, Inc. pays this amount on or before October 3, 2016. The Agreement is personally guaranteed by an officer and majority shareholder of the Company. The outstanding balance at September 30, 2017 was \$0.

Convertible Notes

	September 30, 2017	December 31, 2016
Convertible Note -May 24, 2016	\$ -	\$ 21,900
Convertible Note -August 9, 2016	-	35,000
Convertible Note - October 5, 2016	-	363,768
Convertible Note -November 14, 2016	-	35,000
Convertible Note -November 29, 2016	-	63,260
Less debt discount and debt issuance costs	-	(285,781)
Total	<u>\$ -</u>	<u>\$ 233,147</u>

The Company amortized debt discount and debt issuance costs of \$14,987 and \$38,077 for the three months ended September 30, 2017 and 2016 respectively.

The Company amortized debt discount and debt issuance costs of \$275,407 and \$57,025 for the nine months ended September 30, 2017 and 2016 respectively.

On May 24, 2016, MyDx, Inc. (the "Company") entered into a Convertible Note (the "Note") with Vista Capital Investments, LLC ("Vista") in the Original Principal Amount of \$275,000 (including a 10% Original Issue Discount ("OID")). The Company and Vista agreed to an initial funding under the Note of \$55,000, including an OID of \$5,000 ("Initial Funding"). Future advances under the Note are at the sole discretion of Vista. The Company is only required to repay the amount funded, including the prorated portion of the OID. The note bears interest at the rate of 10% and must be repaid on or before May 24, 2018. The Note may be prepaid by the Company at any time prior to the date, which is 180 days after issuance of the Note at a premium to the amount outstanding at the time of prepayment (as determined in the Note). The Note may be converted by Vista at any time after the six (6) month anniversary of the Note into shares of Company common stock at a conversion price equal to 50% of the market price (as determined in the Note). The Note also contains certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the Note in the event of such defaults. The foregoing is only a brief description of the Note, and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such descriptions are qualified in their entirety by reference to the agreements and their exhibits, which were filed as Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on May 27, 2016.

The issuance of the Note was made in reliance on the exemption provided by Section 4(a)(2) of the Securities Act for the offer and sale of securities not involving a public offering, and Regulation D promulgated under the Securities Act. The Company's reliance upon Section 4(a)(2) of the Securities Act in issuing the securities was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there was only one recipient; (c) there were no subsequent or contemporaneous public offerings of the securities by the Company; (d) the securities were not broken down into smaller denominations; (e) the negotiations for the issuance of the securities took place directly between the individual and the Company; and (f) the recipient of the Note was an accredited investor.

On March 14, 2017, the Company and Vista Capital Investments, LLC ("Vista") entered into a Settlement Agreement dated March 14, 2017 (the "Vista Settlement"). Vista claimed, and the Company disputed, that Vista was still entitled to certain payments pursuant to convertible promissory notes the Company previously issued. On March 13, 2017, Vista submitted a conversion request of 68,437,500 shares of the Company's common stock. Pursuant to the Vista Settlement, the Company issued 35,000,000 shares to Vista on March 14, 2017 and all convertible promissory notes issued by the Company to Vista are now considered paid in full.

The Note might be accelerated if an event of default occurs under the terms of the Note, including the Company's failure to pay principal and interest when due, certain bankruptcy events or if the Company is delinquent in its SEC filings. The Note also contains certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rate under the Note in the event of such defaults. For the nine months ended September 30, 2017, the Company amortized a total of \$2,173 of the debt issuance cost. As of September 30, 2017, the Note had an outstanding balance of \$0 and a remaining unamortized debt discount of \$0.

On August 9, 2016, the Company entered into Securities Purchase Agreement (the "SPA") and Convertible Promissory Note in the original principal amount of \$35,000 (the "Note") with Crown Bridge Partners, LLC ("Crown") pursuant to which Crown funded \$30,000 to the Company after the deduction of a \$3,500 original issue discount and \$1,500 for legal fees. The Note bears interest at the rate of 8% and must be repaid on or before August 9, 2017. The Note may be prepaid by the Company at any time prior to the date which is 180 days after the date of issuance of the Note at a premium to the amount outstanding at the time of prepayment (as determined in the Note). The Note may be converted by Crown at any time after the six (6) month anniversary of the Note into shares of Company common stock at a conversion price equal to 50% of the market price (as determined in the Note). The SPA and Note also contain certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the Note in the event of such defaults.

The issuance of the Note was made in reliance on the exemption provided by Section 4(a)(2) of the Securities Act for the offer and sale of securities not involving a public offering, and Regulation D promulgated under the Securities Act. The Company's reliance upon Section 4(a)(2) of the Securities Act in issuing the securities was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there was only one recipient; (c) there were no subsequent or contemporaneous public offerings of the securities by the Company; (d) the securities were not broken down into smaller denominations; (e) the negotiations for the issuance of the securities took place directly between the individual and the Company; and (f) the recipient of the Note was an accredited investor. For the nine months ended September 30, 2017, the Company amortized a total of \$21,250 of the debt issuance cost. As of September 30, 2017, the Note had an outstanding balance of \$0 and a remaining unamortized debt discount of \$0.

During the nine months ended September 30, 2017, the Note holder elected to convert the Note and accrued interest of \$36,522 into 86,654,550 share of the Company's common stock.

On November 14, 2016, the Company entered into Securities Purchase Agreement (the “SPA”) and Convertible Promissory Note in the original principal amount of \$35,000 (the “Note”) with Crown Bridge Partners, LLC (“Crown”) pursuant to which Crown funded \$31,500 to the Company after the deduction of a \$3,500 original issue discount and \$1,500 for legal fees. The Note bears interest at the rate of 8% and must be repaid on or before August 9, 2017. The Note may be prepaid by the Company at any time prior to the date which is 180 days after the date of issuance of the Note at a premium to the amount outstanding at the time of prepayment (as determined in the Note). The Note may be converted by Crown at any time after the six (6) month anniversary of the Note into shares of Company common stock at a conversion price equal to 50% of the market price (as determined in the Note). The SPA and Note also contain certain representations, warranties, covenants and events of default, and increases in the amount of the principal and interest rates under the Note in the event of such defaults.

The issuance of the Note was made in reliance on the exemption provided by Section 4(a)(2) of the Securities Act for the offer and sale of securities not involving a public offering, and Regulation D promulgated under the Securities Act. The Company’s reliance upon Section 4(a)(2) of the Securities Act in issuing the securities was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there was only one recipient; (c) there were no subsequent or contemporaneous public offerings of the securities by the Company; (d) the securities were not broken down into smaller denominations; (e) the negotiations for the issuance of the securities took place directly between the individual and the Company; and (f) the recipient of the Note was an accredited investor. For the nine months ended September 30, 2017, the Company amortized a total of \$30,577, of the debt issuance cost. As of September 30, 2017, the Note had an outstanding balance of \$0 and a remaining unamortized debt discount of \$0.

During the nine months ended September 30, 2017, the Note holder elected to convert the Note and accrued interest of \$36,749 into 14,699,616 share of the Company’s common stock.

On December 1, 2016, MyDx, Inc. (“MyDx”, or the “Company”) entered into an advisory services agreement (the “Advisory Services Agreement”) and an indemnification agreement (“Indemnification Agreement”) with BCI Advisors, LLC (“BCI”) pursuant to which BCI shall, provide advice and counsel to senior management of the Company on business planning and strategy, restructuring and recapitalization, and consultation to the Board of Directors. BCI will be paid an initial fee of \$50,000 in cash or unrestricted shares of the Company’s Common Stock, and a retainer fee of \$25,000 per month for the eleven (11) months subsequent thereto. In addition, on the 45 and 90th day anniversary of the effectiveness of this Agreement and performance of its services, BCI shall have the right to receive a two (2) year A-1 and A-2 warrant based on a fully diluted basis, each equal to seven-and-one-half percent (7.5%) for a total of (15%) subject to adjustment of the then issued and outstanding Company common shares. The initial fee as well as A-1 and A-2 warrants have been completely earned, free of liens or encumbrances, and non-assessable and can be exercised at any time at an exercise price of \$0.001 per share. This summary contains only a brief description of the material terms of the Advisory Services Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such description is qualified in its entirety by reference to the Advisory Services Agreement. A copy of the Advisory Services Agreement was filed as Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on January 11, 2017. As of September 30, 2017 and December 31, 2016 the balance of this agreement was \$164,182 and \$76,285 respectively.

During the nine months ended September 30, 2017, the Note holder elected to convert the principal of \$137,103 into 140,000,000 share of the Company’s common stock.

Note Payable – Related Party

On December 10, 2015, YCIG, Inc. (“YCIG”), an entity owned and controlled by Daniel Yazbeck, who is an officer, director and major shareholder of the Company, entered into a Loan Agreement (the “Loan Agreement”) with the Company. The Loan Agreement provides that the amounts loaned accrue interest at a rate of 12% per annum and all amounts loaned are due and payable on or before September 29, 2018. The amounts loaned may be prepaid by the Company at any time without penalty. The Loan Agreement provides that in the event of a default, the loan amount becomes immediately due and payable, which may be repaid by the Company in its election in cash or a number of shares of Company common stock equal to four times the amount outstanding at the date of default.

On January 4, 2017 the Company and YCIG. entered into an amendment to the note. The note was modified as follows:

- The note may be repaid by the Company common stock at a conversion price of \$0.0023 or at the close of business on the date of conversion.
- Interest shall be due in a single lump sum payment on June 1, 2017.
- Subsequent to June 1, 2017, all monthly interest payments that accrue shall be payable on the first (1st) day of next month during the remainder life of the Note.

YCIG advanced the Company funds under the loan agreement as follows:

	<u>Outstanding Balances as of</u>	
	<u>September 30,</u> <u>2017</u>	<u>December 31,</u> <u>2016</u>
November 20, 2015	-	15,000
December 1, 2015	-	25,000
December 2, 2015	-	25,000
April 6, 2016	-	10,000
April 27, 2016	-	25,000
July 20, 2016	-	25,000
August 8, 2016	-	25,000
September 19, 2016	-	25,000
December 1, 2016	-	25,000
February 7, 2017	-	-
	<u>\$ -</u>	<u>\$ 200,000</u>

Note Payable

On February 6, 2017, YCIG, Inc. (“Seller”) entered into a purchase and sale agreement where it sold the rights to its loan agreement with the Company to Hasper, Inc. in exchange for the assumption of liabilities under the note and a commitment to fund additional advances to the company. The loans accrue interest at a rate of 12% per annum and all amounts loaned are due and payable on or before September 29, 2018. The amounts loaned may be prepaid by the Company at any time without penalty. The Loan Agreement provides that in the event of a default, the loan amount becomes immediately due and payable, which may be repaid by the Company common stock at a conversion price of \$0.0023 or at the close of business on the date of conversion.

Amendment

On August 22, 2017 the Company and Hasper, Inc. entered into an amendment to the note. The note was modified as follows:

- The facility limit was increased to \$850,000.
- The company received proceeds of \$282,000.
- Fees related to the amendment totaled \$18,500. The fees were recorded as a debt discount and debt issuance costs and will be amortized over the life of the note.

All remaining terms of the Revolving note remained the same.

As of September 30, 2017 and December 31, 2016 the balance of this agreement was \$482,000 and \$0 respectively.

Subsequent to September 30, 2017 the lender converted \$187,750 of the outstanding principal and interest into 82,500,000 share of the company’s common stock.

Due to related party

On February 7, 2017, the Company’s officer made non-interest bearing loans of \$25,000 to the Company in the form of cash. The loan is due on demand and unsecured.

On April 20, 2017, the Company’s officer made non-interest bearing loans of \$20,000 to the Company in the form of cash. The loan is due on demand and unsecured.

On May 8, 2017, the Company's officer made non-interest bearing loans of \$10,000 to the Company in the form of cash. The loan is due on demand and unsecured.

On June 19, 2017, the Company's officer made non-interest bearing loans of \$35,000 to the Company in the form of cash. The loan is due on demand and unsecured.

On June 30, 2017, the Company's officer made non-interest bearing loans of \$45,000 to the Company in the form of cash. The loan is due on demand and unsecured. This was the result of the officer selling 100,000 personal owned shares of Series B Preferred for net proceeds of \$45,000.

On July 17, 2017, the Company's officer made non-interest bearing loans of \$10,000 to the Company in the form of cash. The loan is due on demand and unsecured.

On July 20, 2017, the Company's officer made non-interest bearing loans of \$20,000 to the Company in the form of cash. The loan is due on demand and unsecured.

On August 22, 2017, the Company's officer made non-interest bearing loans of \$45,000 to the Company in the form of cash. The loan is due on demand and unsecured.

During the nine months ended September 30, 2017, the Company has repaid \$90,000. As of September 30, 2017, and December 2016 the Company is reflecting a liability of \$76,075, and \$1,075, respectively.

Settlement of Liabilities

On April 1, 2016, the Company entered into an agreement with a number of external public relations resources ("PR Resources") specializing in shareholder communications and crisis communications in an effort to support the Company's investor communications relating to its convertible debentures, nearly all of which were being converted and sold during this time period thereby causing severe pressure on the stock, as well as the implementation of a number of strategic public relations programs designed to introduce the Company's AquaDx product line by leveraging off the water crisis in Alabama, Flint and Florida. (the "Agreement"). For the requested services, the Company was to pay a one-time payment of Two Hundred Fifty Thousand Dollar (\$250,000) (the "Claim") upon the signing of the Agreement.

On September 30, 2016, the Company accepted performance under the agreement with Lynx Consulting Group, Ltd. ("Lynx Consulting") dated April 3, 2016 (the "Agreement") to render consulting services in connection with the creation and development of MyDx Asia, including staffing an office to develop and expand the Company's business in the Greater China Region. Lynx Consulting's performance included but was not limited to securing the Distribution License Agreement between the Company and its China distribution partners. As consideration for execution of the Agreement, the Company will pay Lynx Consulting a one-time fee of \$1,000,000 for its services plus an incentive fee based on an agreed percentage of the value of the base revenue of contracts produced by Lynx Consulting during the first year of the Agreement, which, at the discretion of the Company, can be paid in cash or shares of common stock.

On October 5, 2016, the Company, Lynx Consulting and Phoenix Fund Management, LLC ("Phoenix Fund") entered into an Assignment and Modification Agreement. Phoenix Fund purchased the debt claim held by Lynx Consulting from MyDx. In settlement of the Claim, the Company shall issue and deliver to Phoenix Fund shares of its common stock as requested by Phoenix Fund, periodically, at a fifty percent (50%) discount from the average closing price of the Company's common stock for the 22 trading days prior to the date of issuance. Upon execution of the assignment, Lynx released MyDx, Inc. from all liabilities under the original note.

In March 2017, the Company sued Phoenix Fund Management, LLC ("Phoenix") to prevent further issuances and conversion notices pursuant to, respectively, a June 2016 \$250,000 Section 3(a)(10) settlement and an October 2016 \$1,000,000 convertible promissory note. Between February 23, 2017 and March 8, 2017, Phoenix submitted five (5) issuance or conversion requests to the Company's transfer agent for a total of 239,188,023 shares of the Company's common stock. As a result of the settlement described below, none of these shares were issued.

On March 10, 2017, the Company entered into a Settlement Agreement with Phoenix dated March 9, 2017 (the "Phoenix Settlement"). Pursuant to the Phoenix Settlement, Phoenix has agreed it is no longer entitled to any shares pursuant to these two agreements, which are now considered paid in full. On March 15, 2017, in connection with the Phoenix Settlement, the Company filed a motion to dismiss the pending lawsuit with the Eleventh Judicial Circuit of Florida. The Company recorded a gain on settlement of debt of \$80,315

On March 13, 2017, the Company and Bright Light Marketing, Inc. (“BLM”), in a settlement related to the Phoenix Settlement, entered into a Settlement Agreement dated March 10, 2017 (the “BLM Settlement”). In 2016, BLM notified the Company that Phoenix was a potential lender. Pursuant to the BLM Settlement, BLM will pay the Company a total of \$217,500 over the next twelve (12) months. BLM is due to pay the first \$100,000 within thirty (30) business days of the signing of the BLM Settlement. BLM will then pay the Company \$10,000 per month on the first day of the next eleven (11) months with the final payment of \$7,500 due on March 1, 2018.

On April 25, 2017, the Company and its previous auditor, BPM LLP (“BPM”), entered into a Settlement Agreement pursuant to which the Company agreed to pay BPM \$80,000 by May 31, 2018. The Company and BPM agreed that, following the Company’s receipt of each new debt or equity investment (including investments paid in tranches over time) by a party who was not, as of April 25, an officer, director, shareholder, or creditor of the Company, the Company shall pay fifteen percent (15%) of the net proceeds to BPM on the first day of the month following receipt of the investment until the \$80,000 has been paid. The Company recorded a gain on settlement of debt of \$70,781. During the nine months ended September 30, 2017 the Company repaid \$0.

On June 16, 2017, the Company issued 500,000 shares valued at \$3,950 for the settlement of an outstanding accounts payable balance of \$4,870. The company recorded a gain on settlement of debt of \$920.

On July 22, 2016, the Company entered into an agreement with Talent Cloud Limited, Hong Kong, (“Talent Cloud”) to provide recruitment services for a Vice President of Business Development for the Company’s Asian market development. At the date of this report, no acceptable candidates have been presented to the Company.

During the year ended December 31, 2016 the Company entered into agreements with Talent Cloud to provide recruitment services for a Community Manager; an APP Manager; and, a Software Developer for the Company’s Asian markets development. The total cost of these services was \$143,900 (the “Claim”).

On September 13, 2016, the Company entered into an agreement with Meyers Associates, L.P. (“Meyers Associates”) to provide support to recruitment services. The total cost of these services was \$10,000 (the “Claim”).

On September 20, 2016, Talent Cloud and Meyers Associates entered into a Claims Purchase Agreement with Rockwell Capital Partners, Inc. (“Rockwell Capital”) to purchase the Claims held by Talent Cloud and Meyers Associates. Rockwell Capital executed a Settlement Agreement whereas the Company and Rockwell Capital agreed to resolve, settle and compromise among other things, the liabilities claimed in the Claims Purchase Agreement. In settlement of the Claim, the Company shall issue freely traded shares of the Company’s common stock as requested by Rockwell Capital, periodically, at a 45% discount from the average lowest closing price for the 15-day trading period preceding the share request.

On October 19, 2016, the Company, Talent Cloud, Meyers Associates, and Rockwell Capital entered into an Assignment and Modification Agreement. Rockwell purchased the debt claim held by Talent Cloud and Meyers Associates from MyDx. In settlement of the Claim, the Company shall issue and deliver to Rockwell shares of its common stock as requested by Rockwell, periodically, at a forty-five percent (45%) discount from the lowest price of the Company’s common stock for the seven trading days prior to the date of issuance. Upon execution of the assignment, Talent Cloud and Meyers Associates released MyDx, Inc. from all liabilities under the original claims.

On November 11, 2016, the Company, Talent Cloud, Meyers Associates, and Rockwell Capital entered into an Assignment and Modification Agreement. Rockwell purchased the debt claim held by Talent Cloud and Meyers Associates from MyDx. In settlement of the Claim, the Company shall issue and deliver to Rockwell shares of its common stock as requested by Rockwell, periodically, at a forty-five percent (45%) discount from the lowest price of the Company’s common stock for the seven trading days prior to the date of issuance. Upon execution of the assignment, Talent Cloud and Meyers Associates released MyDx, Inc. from all liabilities under the original claims.

On November 29, 2016, the Company, Talent Cloud, Good Project, Windset Capital, Next Dimension Technologies, Meyers Associates and Rockwell Capital entered into an Assignment and Modification Agreement. Rockwell purchased the debt claim held by Talent Cloud and Meyers Associates from MyDx. In settlement of the Claim, the Company shall issue and deliver to Rockwell shares of its common stock as requested by Rockwell, periodically, at a forty-five percent (45%) discount from the lowest price of the Company's common stock for the seven trading days prior to the date of issuance. Upon execution of the assignment, Talent Cloud, Good Project, Windset Capital, Next Dimension Technologies, and Meyers Associates released MyDx, Inc. from all liabilities under the original claims.

During the nine months ended September 30, 2016 the Company issued 3,500,000 shares of the Company's common stock to retire \$40,895 of the total claims and recorded a gain on debt settlement of \$198,261.

9. Derivative Liabilities

The Company has identified derivative instruments arising from embedded conversion features in the Company's convertible notes payable and accounts payable at September 30, 2017.

The following summarizes the Black-Scholes assumptions used to estimate the fair value of the derivative liability and warrant liability at the date of issuance and for the convertible notes converted during the nine months ended September 30, 2017.

	Low	High
Annual dividend rate	0%	0%
Expected life	0.02	1.40
Risk-free interest rate	0.51%	1.20%
Expected volatility	102.46%	314.41%

Risk-free interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note with a similar term on the date of the grant.

Dividend yield: The Company uses a 0% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring dividends in the near future.

Volatility: The volatility was estimated using the historical volatilities of the Company's common stock.

Remaining term: The Company's remaining term is based on the remaining contractual maturity of the convertible notes payable and accounts payable.

The following are the changes in the derivative liabilities during the nine months ended September 30, 2017.

	Nine Months Ended September 30, 2017		
	Level 1	Level 2	Level 3
Derivative liabilities as January 1, 2016	\$ -	\$ -	\$ 1,812,441
Addition	-	-	999,921
Conversion	-	-	(1,783,474)
Settlement of debt	-	-	(79,063)
Loss on changes in fair value	-	-	(116,083)
Derivative liabilities as September 30, 2017	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 833,742</u>

The following are the changes in the warrant liability during the nine months ended September 30, 2017.

	Nine Months Ended September 30, 2017		
	Level 1	Level 2	Level 3
Fair value as January 1, 2016	\$ -	\$ -	\$ 247,203
Warrants issued	-	-	(203,199)
Gain on changes in fair value	-	-	(44,004)
Fair value as September 30, 2017	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>

10. Stockholders' Deficit

Reverse Capitalization

Pursuant to the Merger Agreement, upon consummation of the Merger, each share of CDx's capital stock issued and outstanding immediately prior to the Merger was converted into the right to receive one (1) share of Company common stock, par value \$0.001 per share. Additionally, pursuant to the Merger Agreement, upon consummation of the Merger, the Company assumed all of CDx's options and warrants issued and outstanding immediately prior to the Merger, 6,069,960 and 7,571,395 shares of common stock, respectively.

Prior to and as a condition to the closing of the Merger, each then-current Company stockholder agreed to sell certain shares of common stock held by such holder to the Company and the then-current Company stockholders retained an aggregate of 1,990,637 shares of common stock.

Settlement Agreement

On December 23, 2016, the Company entered into a settlement and release agreement (the "Yazbeck Settlement") with Daniel R. Yazbeck, the Chief Executive Officer and Director of the Company ("Yazbeck"), relating to certain bona fide, outstanding, and past-due liabilities of the Company in the aggregate principal amount of approximately \$321,000 for certain unpaid base salary and bonus obligations that remained deferred and/or outstanding, due and owing to Yazbeck.

Under the terms of the Yazbeck Settlement, Yazbeck agreed to forgo and release any claims against the Company under that certain Employment Agreement, by and between Yazbeck and the Company, dated October 15, 2014 (the "Employment Agreement") in exchange for (1) the issuance of fifty-one (51) shares of the Company's Series A Preferred Stock (defined below); (2) the issuance of three hundred thousand (300,000) shares of the Company's Series B Preferred Stock (defined below); (3) a warrant for fifteen percent (15%) of the common shares of the Company issued and outstanding as of January 3, 2017, at an exercise price of \$0.001 per share, with an expiration date of January 3, 2019; and (4) the issuance of thirty million (30,000,000) shares of the Company's restricted common stock.

Preferred Stock

On September 30, 2016, the Company filed a Certificate of Amendment to Articles of Incorporation with the Secretary of State of the State of Nevada to authorize for issuance ten million (10,000,000) shares of blank check preferred stock, par value \$0.001 ("Blank Check Preferred Stock") as included on Form 8-K filed with the SEC on October 4, 2016.

Common Stock

On February 23, 2015, the Company effected a 5-for-1 forward stock split of its issued and outstanding shares of common stock. All share and per share amounts for all periods that have been presented in the condensed consolidated financial statements and notes thereto have been adjusted retrospectively, where applicable, to reflect the forward stock split. The Company filed a Certificate of Amendment to its Certificate of Incorporation which made the forward stock split effective and increased the authorized common shares to 375,000,000 shares with a par value \$0.001 per share.

In April 2015, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement") with CDx Merger Inc., a Nevada corporation and wholly owned subsidiary of the Company ("Merger Sub"), and CDx, Inc. ("CDx"), a Delaware corporation. Pursuant to the Merger Agreement, Merger Sub merged with and into CDx with CDx surviving the merger as the Company's wholly owned subsidiary (the "Merger").

Pursuant to the Merger Agreement, upon consummation of the Merger, each share of CDx's capital stock issued and outstanding immediately prior to the Merger was converted into the right to receive one (1) share of Company common stock, par value \$0.001 per share (the "Common Stock"). Additionally, pursuant to the Merger Agreement, upon consummation of the Merger, the Company assumed all of CDx's options and warrants issued and outstanding immediately prior to the Merger, 6,069,960 and 7,571,395 shares of common stock, respectively. Prior to and as a condition to the closing of the Merger, each then-current Company stockholder agreed to sell certain shares of common stock held by such holder to the Company and the then-current Company stockholders retained an aggregate of 1,990,637 shares of common stock. Therefore, following the Merger, CDx's former stockholders now hold 19,855,295 shares of Company common stock which is approximately 91% of the Company common stock outstanding.

Pursuant to the Merger Agreement, each party has made certain customary representations and warranties to the other parties thereto. The Merger was conditioned upon approval by CDx's stockholders and certain other customary closing conditions.

On April 24, 2015, in anticipation of closing the Merger, the Company changed its name to MyDx, Inc. On April 30, 2015, the Merger was consummated. Upon consummation of the Merger, the Company expanded its board of directors (the "Board") from one to seven directors, each of whom will be directors designated by CDx.

The Merger is being treated as a reverse acquisition of the Company, a public shell company, for financial accounting and reporting purposes. As such, CDx is treated as the acquirer for accounting and financial reporting purposes while the Company is treated as the acquired entity for accounting and financial reporting purposes. Further, as a result, the historical financial statements that will be reflected in the Company's future financial statements filed with the United States Securities and Exchange Commission ("SEC") will be those of CDx, and the Company's assets, liabilities and results of operations will be consolidated with the assets, liabilities and results of operations of CDx.

Each share of common stock has the right to one vote. The holders of common stock are entitled to dividends when funds are legally available and when declared by the board of directors.

As a result of the Merger, the Company issued a total of 19,855,295 share of common stock to the shareholders of CDx.

On September 30, 2016, the Company amended articles of incorporation to increase the number of authorized commons shares to 10,000,000,000 as included on Form 8-K filed with the SEC on October 4, 2016.

During the nine months ended September 30, 2017, the Company issued 144,000,000 shares of common stock in exchange for services at a fair value of \$473,800. During the nine months ended September 30, 2016, the Company issued 1,461,906 shares of common stock in exchange for services at a fair value of \$253,060.

On March 16, 2017, the Company entered into a securities purchase agreement ("SPA") with TLG, Inc, and TRD, Inc. ("Investors") pursuant to which the Company agreed to sell 25,000,000 restricted shares of the Company's common stock, in an above market transaction at a purchase price of \$0.004 per share for a total of \$100,000. As part of the SPA, the Company granted the Investors the option, within the next 60 days, to purchase an additional 25,000,000 of restricted shares of the Company's common stock at a purchase price of \$0.006 per share for a total of \$150,000. The shares of Common Stock issued pursuant to the Subscription Agreement have not been registered under the Securities Act of 1933, as amended (the "Securities Act") and are "restricted securities" as that term is defined by Rule 144 promulgated under the Securities Act. Pursuant to the securities purchase agreement, the Investors agreed not to sell more than three hundred and seventy-five thousand shares per day (subject to adjustment for forward and reverse stock splits that occur after the date hereof) or more than seven million five hundred thousand shares per month (subject to adjustment for forward and reverse stock splits that occur after the date hereof) of the securities purchased pursuant to the SPA. On May 1, 2017, the Company entered into an amendment to the TLG, Inc SPA. The modification allowed TLG, Inc to purchase a total of 25,000,000 of restricted shares of the Company's common stock at a purchase price of \$0.006 per share for a total of \$150,000. TLG exercised all of these options on May 2, 2017.

Common Stock Warrants

During the nine months ended September 30, 2017, the Company agreed to issue warrants to purchase 252,773,754 shares of common stock. During the nine months ended September 30, 2016, the Company did not issue any warrants to purchase shares of common stock. No common stock warrants have been exercised or have expired and warrants to purchase 260,345,149 shares of common stock were outstanding as of September 30, 2017.

2015 Equity Incentive Plan

In connection with the Merger on April 30, 2015, the Company adopted the MyDx, Inc. 2015 Equity Incentive Plan (the “2015 Plan”), and to date, has reserved 6,200,000 shares of common stock for issuance under the 2015 Plan. Under the 2015 Plan, employees, directors or consultants may be granted nonstatutory stock options, stock appreciation rights, restricted stock and restricted stock units to purchase shares of MyDx’s common stock. Only employees are eligible to receive incentive stock options (“ISO”) to purchase common stock. Vesting and exercise provisions are determined by the Board of Directors at the time of grant. The options generally expire ten years from the date of grant. ISOs granted to a participant who, at the time the ISO is granted, has more than 10% of the voting power between all classes of stock, will expire five years from the date of grant. Options vest at various rates ranging from immediately to three years. As of September 30, 2017, options to purchase 1,573,755 shares were available under the 2015 Plan for issuance.

A summary of the Company’s stock option plan for the nine months ended September 30, 2017 was as follows:

	Shares	Weighted-Average Exercise Price
Outstanding as of December 31, 2016	1,490,000	\$ 0.48
Granted	-	\$ -
Exercised	-	\$ -
Forfeited or cancelled	-	\$ -
Outstanding as of September 30, 2017	<u>1,490,000</u>	<u>\$ 0.27</u>
Options exercisable as of September 30, 2017	<u>1,408,333</u>	<u>\$ 0.25</u>

The aggregate intrinsic value of options exercised was \$0 and \$0 for the nine months ended September 30, 2017 and 2016, respectively.

Information regarding options outstanding and exercisable as of September 30, 2017, is as follows:

Exercise Price	Options Outstanding			Options Exercisable		
	Number Outstanding	Average Remaining Contractual Life (Years)	Weighted-Average Exercise Price	Number Outstanding	Weighted-Average Exercise Price	
\$ 0.08	900,000	3.86	\$ 0.08	900,000	\$ 0.08	
\$ 0.55	515,000	3.41	\$ 0.55	433,333	\$ 0.55	
\$ 0.57	75,000	3.99	\$ 0.57	75,000	\$ 0.57	
	<u>1,490,000</u>	3.8	\$ 0.27	<u>1,377,916</u>	\$ 0.27	

Total unrecognized compensation expense from employee stock options as of September 30, 2017 was \$2,927 and will be recognized over a weighted average recognition period of 0.70 years.

Total stock-based compensation expense, both employee and non-employee, recognized by the Company for the nine months ended September 30, 2017 and 2016 was \$9,257 and \$377,669 respectively. Stock-based compensation expense related to stock options granted to non-employees for the nine months ended September 30, 2017 and 2016 was \$4,867 and \$37,607 respectively. No tax benefits were recognized in the nine months ended September 30, 2017 and 2016.

11. Commitments and Contingencies

Distribution and License Agreement and Joint Development Agreements

The Company entered into a Distribution and License Agreement with a third-party for the purpose of developing a sensor array to be used in the Company’s product. The Distribution and License Agreement has an initial term of ten years, but can be terminated earlier if the project does not meet the specifications of the Company. The Company will obtain exclusive rights to sell and distribute once a successful sensor prototype is developed. In exchange for a functional prototype, the Company will pay the third-party a 7% royalty on net sales. During the nine months ended September 30, 2017 and 2016, the Company did not incur any development costs related to the Distribution and License Agreement.

On November 1, 2013, the Company entered into a two-year Joint Development Agreement (the “Agreement”) with an unrelated third-party to develop chemical sensors and peripheral sensing equipment and software for the detection and characterization of cannabis and compounds associated with cannabis.

The Agreement provides for, among other things, any arising intellectual property rights (as defined) outside of the field (as defined), and any arising intellectual property rights relating to improvements to detection materials shall belong to the Joint Venture Developer.

The Agreement also provides that any arising intellectual property rights other than those covered above shall belong to the Company. To the extent that it is necessary to do so to enable the Company to use and exploit its respective arising intellectual property rights, the Joint Developer grants the Company a perpetual, irrevocable, exclusive, and royalty free license (including the right to assign the license and to grant sub-licenses) to use and exploit the Joint Developer’s arising intellectual property rights in the field. Under the terms of the Agreement, either party may cancel the Agreement as the specific tasks provided for in the Agreement have been completed or for causes specifically provided for in the Agreement. During the years ended December 31, 2015 and 2014, the Company paid the Joint Developer \$200,000 and \$227,500 for development costs, respectively.

On May 19, 2015, the Company entered into an Exclusive Patent Sublicense Agreement (the “License Agreement”) with Next Dimension Technologies, Inc. (“NDT”). The License Agreement grants the Company a worldwide right to the patents licensed by NDT from the California Institute of Technology. The License Agreement grants both exclusive and non-exclusive patent rights. The license granted in the License Agreement permits the Company to make, have made, use, sell and offer for sale sublicensed products in the field of use. The License Agreement continues until the expiration, revocation, invalidation or enforceability of the rights licensed. The License Agreement provides for the payment of a license fee and royalty payments by CDx to NDT. The License Agreement also contains minimum royalty payments and milestone payments by CDx to NDT. NDT has a right to terminate the License Agreement in the event of an uncured breach by CDx; the insolvency or bankruptcy of CDx; or if CDx does not meet certain productivity milestones. The License Agreement also contains representations, warranties and indemnity obligations for each of CDx and NDT. In connection with the License Agreement, on May 19, 2015, CDx and NDT also executed an Amended Amendment No. 4 (the “Amended Amendment No. 4”) to the Joint Development Agreement, dated as of November 1, 2013, between CDx and NDT, which extended the date of negotiation for the License Agreement through May 19, 2015.

On February 8, 2017, MyDx, Inc. entered into an option agreement (the “Option Agreement”) with the Torque Research & Development, Inc. (“TRD”). The Option Agreement provides MyDx with the exclusive right to license two patent pending inventions (the “TRD Inventions”), and requires MyDx to make annual payments to TRD as well as royalty payments on any products that are commercialized which are based on the TRD Inventions. MyDx’s rights under the Option Agreement require customary measures of performance on the part of MyDx in terms of patent cost maintenance and other payments of costs associated with the TRD Inventions. With respect to the Option Agreement, MyDx rights are broad in terms of the potential access MyDx has to use the TRD Inventions in products, and services and many of the key economic terms of a future license, should MyDx exercise its rights under the Option Agreement, are agreed to in the Option Agreement.

In addition to the Option Agreement with the TRD, on February 8, 2017, MyDx has entered into a research and development agreement (the “RD Agreement”) with TRD for the Project titled “Manufacturable, Medical Grade Smart Vape Devices and Related Medical Software Applications for Prescribers, Administrators and Patient Applications.” The RD Agreement allows MyDx to fund research based on the TRD Inventions with a three year budget of \$280,371 and a deferred payment of \$75,000 within ninety days of the Effective Date. The RD Agreement provides MyDx with an exclusive right to license all technology that is discovered from the monies funded to TRD through the RD Agreement (the “Derivative IP”). To the extent that MyDx exercises its rights under the RD Agreement, MyDx will be required to make customary annual payments to TRD, who shall be the owners of any Derivative IP, as well as royalty payments as any commercialization of such Derivative IP occurs. TRD may elect to accept payment in whole or in part in cash or the companies restricted common stock priced at the Effective Date.

License and Distribution Agreement

On September 1, 2016, MyDx, Inc. (the “Company” or “Licensor”) entered into a Distribution and License Agreement (the “License Agreement”) with Powerfull Holdings, Ltd, a company operating under the charter of the People’s Republic of China (“Assignor”) and China Science and Technology, a Powerfull Holdings affiliated Company (“Licensee”), (together the “Parties”). The Parties intend there to be two phases of the License Agreement: Phase One and Phase Two. During Phase One, the Licensor shall provide test samples and validation data for market validation. Subject to Phase One producing satisfactory results, and proof of concept, the Parties will commence Phase Two.

For Phase One, the Licensee will pay the Licensor a minimum of Forty-Five Thousand Dollars (\$45,000.00) as a Licensing and Technology Transfer Fee (the "Transfer Fee") per application (AquaDx™, OrganaDx™, AeroDx™). These fees shall be credited towards Phase Two's mandatory minimum payments. The Licensee shall pay the Transfer Fee within 10 business days of being provided with an invoice by the Licensor. However, should the Parties determine that the results of the activities of Phase One were not satisfactory to both parties, this Agreement shall terminate pursuant to Section 7.2(b).

In connection with the agreement referenced above, the licensor and licensee are currently still operating under Phase I and the company has not yet received adequate information to enter Phase II. MyDx has not yet received and has requested market feasibility, regulatory and other studies from Licensee as contemplated under the agreement and has requested the results of their Phase I findings to be delivered to Company on or before April 21, 2017. To the extent MyDx management is unable to receive satisfactory results and confirm proof of concept, MyDx has notified Licensee it will be difficult to continue under the current agreement and the parties are permitted to terminate for cause and defectiveness in the event the products do not pass tests for quality, reliability, efficacy, and marketability or if at the completion of Phase I, the results were not satisfactory and the concept was not proven.

Effective as of April 21, 2017, the Company terminated its Distribution and License Agreement (the "License Agreement") with China Science and Technology ("Licensee") entered into in September 2016. The Company terminated the License Agreement due to the Company not receiving confirmation of proof of concept from the Licensee for deployment of the Company's products in China.

On June 12, 2017, MyDx, Inc. (the "Company" or "Licensor") entered into a license and services agreement (the "License Agreement") with Black Swan, LLC (the "Licensee"). The Licensor agrees to grant to the Licensee the Access License which shall consist of:

- (a) access to the Database to enable Licensee to engage in formulation queries regarding the effects of having different amounts of terpene or other chemicals in cannabis strains;
- (b) access to the Database's chemical profile library and related definitions;
- (c) access to a list with the contact information and fee schedule of cannabis extractors with state licenses so that Licensee can submit the formulation query results to such licensed cannabis extractors. Such licensed extractor list may change and Licensor shall have no obligation to provide Licensee with an updated list; and
- (d) access to the CannaDx™ mobile application to track feedback and reviews by up to 20,000 users of Licensee's products.

The Licensor will provide the Product Services which shall consist of:

- (1) Licensor providing annual MyDx360 SAAS Premium Subscription at a cost of \$15,000 per annum
- (2) Licensor providing 6,000 Cartridges every six months to the Licensee at a cost of \$2.49 per Cartridge (\$14,940 in total every six months). It shall be a requirement of this Agreement that Licensee order 6,000 Cartridges from Licensor every six months;
- (3) Licensor providing 1,000 Eco Smart Pens to the Licensee, when available, over the three-year term of this Agreement at a cost of \$25 per Eco Smart Pen (\$25,000 in total); and
- (4) Licensor providing 6,000 batteries to the Licensee over the three-year term of this Agreement at a cost of \$3.99 per battery (\$23,940 in total).

The term of this Agreement shall be three (3) years. Licensor shall have the right, in its sole discretion, to terminate this Agreement if Licensee does not order and pay for at least 6,000 Cartridges every six months at a cost of \$2.49 per Cartridge (\$14,940 in total every six months).

Marketing and Advertising Advisory Services Agreement

On April 5, 2016, the Company entered into a Marketing and Advertising Advisory Services Agreement (the “Agreement”) with Growth Point Advisors, Ltd. (“Growth Point”) for Growth Point to provide a comprehensive marketing, advertising and branding campaign for the Greater China Region on behalf of the Company’s MyDx AquaDx sensor. The campaign shall include, but not be limited to, the development of both the front and back-end of an e-commerce web site targeting the Chinese audience as well as introductions to potential key personnel to launch and manage the campaign.

In consideration for the services described above, the Company shall pay Growth Point a monthly service fee of \$30,000. Should the Company fail to pay the monthly service fee, Growth Point shall have the right to convert the monthly service fee into the Company’s common stock at a 50% discount of the lowest closing price of the Company’s common stock for the 15 trading days upon send notice of non-payment to the Company.

On May 16, 2017, the Company terminated its Marketing and Advertising Advisory Services Agreement with Growth Point Advisors, Ltd. (“Growth Point”) entered into in April 2016. Growth Point had been expected to provide a comprehensive marketing, advertising and branding campaign for the Greater China Region on behalf of the Company’s MyDx AquaDx sensor. Growth Point failed to satisfy the agreed upon deliverables as stated in the agreement. As of the date of this filing the Company has not received communication from Growth Point.

On February 17, 2017 MyDx and Libre Design, LLC (“LDL”) entered into a twelve (12) month Research, Branding, Advertising and Marketing Services Agreement (“Agency Agreement”). The Company agreed to pay deferred cash compensation as follows of three thousand dollars (\$3,000) upon execution and one thousand five hundred dollars (\$1,500) per month for a subsequent eleven (11) payments thereafter on or before the first (1st) of each month. In addition, Agency is entitled to receive sixty seven million shares of restricted common stock at a closing market price equal to \$0.0011.

On March 1 and 15th, 2017, MyDx, Inc. received a payment demand for the initial and subsequent payment of \$50,000 and \$25,000 per month respectively, exclusive of costs and other fees, due and owing under the BCI Advisors, LLC (“BCI”) advisory services agreement (the “Advisory Services Agreement”). The Company elected in lieu of cash to pay in unrestricted common stock, registered in form S-8. The Company made an initial payment of seventy five million shares in partial satisfaction of the amount due and owing that does not exceed the Company’s obligations under the Advisory Services Agreement to restrict BCI’s beneficial ownership to 4.99%. This summary contains only a brief description of the material terms of the Advisory Services Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder, and such description is qualified in its entirety by reference to the Advisory Services Agreement. A copy of the Advisory Services Agreement was filed in a Current Report on Form 8-K.

Resale Licensing Agreement

On October 4, 2016, the Company executed a Resale Licensing Agreement with ANP Technologies, Inc. (“ANP”) (the “Agreement”) that outlines the terms and conditions for a One-Time, Non-Exclusive Resale License to MyDx, Inc. for the sale of ANP’s ACE-III-C pesticide and toxic heavy metal Lateral Flow Assay detection test under MyDx, Inc.’s brand. The Agreement provides for the purchase and resale of 10,000 units as part of a Phase I validation of the product’s merchantability. On June 9, 2017, the Company and ANP terminated the Resale Licensing Agreement.

Acquisition Agreement

On February 10, 2017, the Company entered into a binding term sheet to acquire certain trademarks, software, data and customer lists from Bud Genius, Inc. In good faith, the parties agreed to complete all due diligence and execute transaction documents within 45 days of the date hereof. As of November 8, 2017, the transaction documents have not yet been executed.

Litigation

In the normal course of business, the Company may be subject to other legal proceedings, lawsuits and other claims. Although the ultimate aggregate amount of probable monetary liability or financial impact with respect to these matters is subject to many uncertainties and is therefore not predictable with assurance, the Company’s management believes that any monetary liability or financial impact to the Company from these other matters, individually and in the aggregate, would not be material to the Company’s financial condition, results of operations or cash flows.

However, there can be no assurance with respect to such result, and monetary liability or financial impact to the Company from these other matters could differ materially from those projected.

12. Subsequent Events

The Company and Phylos Bioscience, Inc. (“Phylos”) entered into a License, Co-Marketing, and Data Sharing Agreement on November 3, 2017 (the “Phylos Agreement”). Pursuant to the Phylos Agreement, the Company and Phylos each granted a non-exclusive license to the other party to access their data and use their trademarks and logo on marketing materials. Neither party paid cash or issued shares in connection with the Phylos Agreement. The license was the consideration given by each party. The term of the agreement is five (5) years.

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND PLAN OF OPERATIONS

The following discussion and analysis should be read in conjunction with, and is qualified in its entirety by, MyDx's audited annual financial statements and the related notes thereto as filed with the Securities and Exchange Commission ("SEC") on April 20, 2017, as amended on April 26, 2017. This discussion contains certain forward-looking statements that involve risks and uncertainties, as described under the heading "Forward-Looking Statements" in this quarterly report. Actual results could differ materially from those projected in the forward-looking statements. For additional information regarding these risks and uncertainties, please see the disclosure under the heading "Risk Factors" elsewhere in this quarterly report.

The Management Discussion and Analysis of Financial Condition and Results of Operations below is based upon only the financial performance of MyDx. MyDx's financial statements for the three and nine months ended September 30, 2017 and the audited results of operations of MyDx for the period ended December 31, 2016.

We believe that our assumptions are based upon reasonable data derived from and known about our business and operations and the business and operations of the Company. No assurances are made that actual results of operations or the results of our future activities will not differ materially from its assumptions. Factors that could cause differences include, but are not limited to, expected market demand for the Company's products and services and competition.

The Merger between MyDx, Inc. and CDx, Inc. ("CDx"), consummated on April 30, 2015, was treated as a reverse acquisition for financial accounting and reporting purposes. As such, CDx is treated as the acquirer for accounting and financial reporting purposes while MyDx, Inc. was treated as the acquired entity for accounting and financial reporting purposes. Further, as a result, the historical financial statements that will be reflected in the Company's future financial statements filed with the SEC will be those of CDx, and the Company's assets, liabilities and results of operations will be consolidated with the assets, liabilities and results of operations of CDx. Accordingly, for clarity and continuity, we are presenting the historical financial statements for CDx, Inc. for the periods presented.

Overview

MyDx is a science and technology company that develops and deploys products and services in the following focus areas:

- 1) **Consumer Products** – smart devices and consumables
- 2) **Data Analytics** – pre-clinical chemical analysis and patient feedback ecosystem
- 3) **Biopharmaceuticals** – identifying 'green Active Pharmaceutical IngredientsTM, (gAPITM) and corresponding formulations
- 4) **Software as a Service (SaaS)** – Software services for prescribers, patient groups, cultivators, and regulators

We are committed to addressing areas of critical national need to promote public safety, transparency and regulation in the various markets we serve.

The Company's first product, MyDx[®], also known as "My Diagnostic", is a multiuse hand-held chemical analyzer made for consumers and professional users which feeds our data analytics platform and SaaS business. MyDx is intended to allow consumers to Trust & Verify[®] what they put into their mind and body by using our science and technology to test for pesticides in food, chemicals in water, toxins in the air, and the safety and potency of cannabis samples, which is our initial focus.

The Company's founder, sole officer and sole member of the Board of Directors, Daniel Yazbeck, is an experienced executive with over 15 years of product research, development and commercialization experience including at Fortune 500 companies. Mr. Yazbeck was a scientist for Pfizer Pharmaceuticals, specializing in Chemical R&D technologies that identify and manufacture Active Pharmaceutical Ingredients at scale using green chemistry and a strategic product and market developer for Panasonic, engineering new consumer electronic products and deploying them with strategic partners in the healthcare industry. Mr. Yazbeck is also a seasoned asset-backed investor at Yazbeck Investments and holds a master of science degree from McGill University.

MyDx, and its wholly owned subsidiary, CDx, has successfully executed on a four-year business plan. The Company has received cash investment of approximately \$9 million to date. In 2013, CDx was established with \$210,000 in seed funding and resource support from an entity affiliated with Mr. Yazbeck to secure strategic development partners and establish a market, product and initial IP portfolio. In 2014, CDx developed, protected, manufactured and marketed the beta version of its first product, the MyDx Analyzer, through a crowdfunding campaign that launched in January 2014 as well as a financing round where \$600,000 of shares of CDx, Inc. Series A Preferred Stock was sold through April 2014 and \$2 million in convertible notes were issued through September 2014. The Beta product was released in the first quarter of 2015, at which point \$4,800,000 of shares of Series B Preferred Stock in CDx, Inc. was sold followed by the completion of the Merger with MyDx, Inc., whose shares of common started to trade on the OTCQB marketplace. The official product was released in the third quarter of 2015 and the Company received an additional \$250,000 loan from the same entity affiliated with Mr. Yazbeck to help finance its operations in the fourth quarter. In 2016, we believe the Company continued to penetrate its market and increased brand recognition. Since the MyDx Analyzer's launch in 2015 it has generated close to \$1.2M in revenues. In addition, in 2016, the Company launched additional products that tests for pesticides in food and chemicals in water and financed the company's operations primarily through the issuance of convertible debt, the majority of which had been satisfied as of March 31, 2017.

Business Plan

The Company is currently focused on 4 key business segments to service the cannabis industry.

1. Consumer Products

Smart Devices & Consumables

1) CannaDx™

- The cannabis industry's first hand-held cannabis sensor and analyzer with disposable single use inserts.
- Comes with a mobile app that acts as a 'virtual budtender'.
- Analyzes cannabis sample and provides a Total Canna Profile™ (TCP), a more complete chemical profile to include THC and the most prevalent cannabinoids and terpenes found in cannabis plants.
- Cannabinoids such as THC and CBD have been reported to bind the CB1 and CB2 receptors found throughout the human body and have been reported to provide relief to an array of symptoms, including pain, nausea, and inflammation to name a few. Terpenes, which have been reported to compound the effects of cannabinoids on the body via an "Entourage Effect", are also important in determining the overall physiological effects various cannabis chemical profiles.
- Enables users to log their ailments and side effects and tie those back to the exact chemical profile
- Provides strain recommendations based on desired "relief" input based on crowdsourced community feedback.

2) Eco Smart Pen™ and Other Delivery Devices

- MyDx plans to develop additional smart hardware that gather user data, such as the Eco Smart Pen
- Integrated with Bluetooth as well as other technologies that will allow for mobile-app control, dose restrictions, safety controls, and usage statistics.
- We plan to OEM these product to third-party customers

3) MyDx Tablet Edition

- MyDx plans to develop the first touchscreen kitchen tablet in the market with integrated MyDx sensor reading capability
- Sensor lineup to include OrganaDx, AquaDx, and AeroDx.
- Company plans to offer CannaDx data portal management ability in MyDx Tablet Edition .

MyDx plans to evaluate the 510K FDA device approval process to leverage its consumer products and the ability of insurance companies to support sales of its smart devices and generate HIPPA compliant crowdsourced data.

2. Data Analytics

Pre-Clinical Chemical Analysis and Patient Feedback Ecosystem

MyDx will have four classes of data and algorithms:

1) User Data

- When users download the CannaDx mobile app, we may ask them put in personal details such as gender, location, height, weight, age etc. that we maintain while complying with HIPAA.

2) Chemical Composition Data

- This information is sourced from a number of inputs including the CannaDx Handheld's Total Canna Profile (TCP), partner laboratories analyses, and branded pre-tested concentrates.

3) User Feedback

- Provided by users in our CannaDx mobile app as they try various products and record their experiences with those products.

4) Usage Statistics

- We will capture type, frequency, dosage, ailments relieved, and side effects.

MyDx plans to leverage this data, which combined is referred to as the Total Canna Profile™ (TCP), combined with our proprietary algorithms, to develop key insights into user behavior based on unique chemical profiles. Our goal is to track how a specific sample is expected to help relieve certain ailments and to validate the results.

3. Biopharmaceutical

Identifying 'green Active Pharmaceutical Ingredients™, (gAPI™) and corresponding formulations

1) Sale and License of Product Formulations

- MyDx plans to work with third party customers to license crowdsourced formulated chemical profiles that are expected to address a specific "relief" desired using its own proprietary formulas derived from our extensive dataset and algorithms.

2) Sale of green Active Pharmaceutical Ingredients (gAPI™)

- This division will also look to provide an organic source of extracted green Active Pharmaceutical Ingredients (gAPI™), such as a predefined terpene formulation, for consumer and industrial use.
- Given that certain classes of gAPI's such as hemp derived CBD and terpenes might offer "relief" without the "high" THC provides, MyDx intends to partner with leaders in the industry to offer branded products without THC, akin to a "virgin" cocktail, if it finds that these formulations offer the benefits desired and the legal framework to sell them is viable.

4. SaaS (Software as a Service)

Software services for prescribers, patient groups, cultivators, and regulators

1) MyDx App

- Available in iOS and Android and controls the MyDx Analyzer
- Tracks patient tested samples and physiological feedback
- Prints a Certificate of Analysis, which includes patient feedback
- Offers patients groups and their doctors with OEM software to track what the community is experiencing
- Centrally hosted in our secure cloud based server
- Will offer in App purchases for additional software subscription features

2) Software to Support Laboratory Marketing, Customer Service and Data Aggregation

- MyDx will offer what we believe will be the premier lead generator and outsourced services provider for cannabis testing labs
- Through certain assets MyDx expects to develop or acquire, as well as leads generated from our handheld analysis and smart devices, we believe MyDx will be positioned to become a world leader in cannabis laboratory marketing and services and as the largest "data holder" of tested cannabis and the associated chemical profiles tied to the ailment therapy.

Recent Developments

Effective as of April 21, 2017, the Company terminated its Distribution and License Agreement (the “License Agreement”) with China Science and Technology (“Licensee”) entered into in September 2016. The Company terminated the License Agreement due to the Company’s belief that it did not receive confirmation of proof of concept from the Licensee for deployment of the Company’s products in China.

On April 25, 2017, the Company and its previous auditor, BPM LLP (“BPM”), entered into a Settlement Agreement pursuant to which the Company agreed to pay BPM \$80,000 by May 31, 2018. The Company and BPM agreed that, following the Company’s receipt of each new debt or equity investment (including investments paid in tranches over time) by a party who was not, as of April 25, an officer, director, shareholder, or creditor of the Company, the Company shall pay fifteen percent (15%) of the net proceeds to BPM on the first day of the month following receipt of the investment until the \$80,000 has been paid. The company recorded a gain on settlement of debt of \$70,781. During the nine months ended September 30, 2017 the company repaid \$0.

On May 16, 2017, the Company terminated its Marketing and Advertising Advisory Services Agreement with Growth Point Advisors, Ltd. (“Growth Point”) entered into in April 2016. Growth Point had been expected to provide a comprehensive marketing, advertising and branding campaign for the Greater China Region on behalf of the Company’s MyDx AquaDx sensor.

Results of Operations

As shown in the accompanying consolidated financial statements, the Company incurred net losses of \$392,409 and \$2,524,873, respectively, for the three and nine months ended September 30, 2017 and \$2,866,810 and \$4,347,986, respectively, for the three and nine month periods ended September 30, 2016, respectively, and had an accumulated deficit of \$28,924,326 as of September 30, 2017.

Comparison of Three Months Ended September 30, 2017 and 2016

Revenue

For the three months ended September 30, 2017 and 2016, the Company had licensing revenue of \$4,315 and \$0, respectively. For the three months ended September 30, 2017 and 2016, the Company had product revenue of \$104,650 and \$134,240, respectively. The decrease in revenue for the three months ended September 30, 2017 compared to 2016 correlated to a large order from its newly signed distribution partner in 2016 as well as an exceptionally large volume of global media coverage for that quarter compared to the same quarter in 2017.

Cost of Goods Sold and Gross Profit

Gross profit as a percentage of net revenues for the three months ended September 30, 2017 and 2016 were 68% and 40.8%, respectively. The gross margin was positively affected by a decrease in accrued royalties, as well as the increase in the amount of Grower’s Packages sold as well as more direct to consumer sales compared to sales via distributors.

Operating Expenses

For the three months ended September 30, 2017, the Company incurred operating expenses in the amount of \$283,951 compared to \$1,976,382 for the three months ended September 30, 2016. These operating expenses were composed of research and development costs, sales and marketing and general and administrative expenses. The decrease mainly resulted from the decrease of general and administrative expenses, research and development costs and marketing activities.

Research and Development Expenses

Research and development expenses primarily consist of engineering and product development, incurred in the design, development, testing and enhancement of our products. For the three months ended September 30, 2017, the Company expended \$39,595 for various research and development projects for hardware, database, software and sensor development as compared to \$111,315 for the three months ended September 30, 2016. The decrease of \$71,720, or 64%, resulted primarily from the Company taking a more economical and streamlined outsourcing approach to developing new products (such as the Eco Smart Pen™) as well as improving existing products, including CannaDx™, AquaDx™ and OrganaDx™.

Sales and Marketing Expenses

Sales and marketing expenses consist primarily of consulting fees for third-party services and general marketing expenses. For the three months ended September 30, 2017, the Company expended \$68,420 as compared to \$1,588,884 for the three months ended September 30, 2016. The decrease of \$1,520,464, or 96%, resulted primarily from the Company expanding brand awareness surrounding its new product lines using more economical PR and social media marketing channels targeting Canada as compared to the costlier product expansion collaboration models entered into in 2016.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries, wages and benefits, consulting fees, legal fees, accounting fees and general administrative expenses.

For the three months ended September 30, 2017, the Company expended \$175,936 as compared to \$276,183 for the three months ended September 30, 2016. The decrease of \$10,246, or 31%, resulted primarily from decreases in accounting fees, investor relation fees, legal fees, and miscellaneous general administrative expenses.

Other income (expense)

Other expenses decrease by \$760,753, resulted primarily from the decrease of interest expense related to the convertible notes payable, an increase in a loss on fair value of derivative liability, and a loss on settlement of debt. These were offset by an increase in derivative expense.

Comparison of Nine Months Ended September 30, 2017 and 2016

Revenue

For the nine months ended September 30, 2017 and 2016, the Company had licensing revenue of \$4,315 and \$68,000, respectively. For the nine months ended September 30, 2017 and 2016, the Company had product revenue of \$315,851 and \$506,880, respectively. The decrease in revenue for the nine months ended September 30, 2017 compared to 2016 correlated to a large order from its newly signed distribution partner in the nine months ended September 30, 2016 as well as an exceptionally large volume of global media coverage for those nine months compared to the same nine months in 2017.

Cost of Goods Sold and Gross Profit

Gross profit as a percentage of net revenues for the nine months ended September 30, 2017 and 2016 were 70% and 50.4%, respectively. The gross margin was positively affected by a decrease in accrued royalties.

Operating Expenses

For the nine months ended September 30, 2017, the Company incurred operating expenses in the amount of \$1,869,965 compared to \$3,561,343 for the nine months ended September 30, 2016. These operating expenses were composed of research and development costs, sales and marketing and general and administrative expenses. The decrease mainly resulted from the decrease in sales and marketing activities, general and administrative expenses and research and development costs.

Research and Development Expenses

Research and development expenses primarily consist of engineering and product development, incurred in the design, development, testing and enhancement of our products. For the nine months ended September 30, 2017, the Company expended \$87,602 for various research and development projects for hardware, database, software and sensor development as compared to \$352,407 for the nine months ended September 30, 2016. The decrease of \$264,805, or 75%, resulted primarily from the Company taking a more economical and streamlined outsourcing approach to developing new products (such as the Eco Smart Pen™) as well as improving existing products, including CannaDx™, AquaDx™ and OrganaDx™.

Sales and Marketing Expenses

Sales and marketing expenses consist primarily of consulting fees for third-party services and general marketing expenses. For the nine months ended September 30, 2017, the Company expended \$741,813 as compared to \$1,792,496 for the nine months ended September 30, 2016. The decrease of \$1,050,683, or 59%, resulted primarily from the Company expanding brand awareness surrounding its new product

lines using more economical PR and social media marketing channels targeting Canada as compared to the costlier product expansion collaboration models entered into in 2016.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries, wages and benefits, consulting fees, legal fees, accounting fees and general administrative expenses.

For the nine months ended September 30, 2017, the Company expended \$1,040,550 as compared to \$1,416,440 for the nine months ended September 30, 2016. The decrease of \$375,890, or 27%, resulted primarily from decreases in accounting fees, investor relation fees, legal fees, and miscellaneous general administrative expenses. These decreases were offset by an increase in consulting fees.

Other income (expense)

Other (expense) decrease by \$193,452, resulted primarily from the decrease in interest expense related to the convertible notes payable, decrease in gain on fair value of derivative liability and derivative expense. These were offset by an increase from the gain on settlement of debt, and a gain on forfeiture of technology transfer deposit.

Liquidity and Capital Resources

Since its inception, capital raised by the Company has been used primarily for the Company's research and development efforts and to support its operations. As of September 30, 2017, the Company had remaining cash of \$162,451 with a net working capital deficit of \$1,856,616. As a result of the Company's significant operating expenditures and the lack of significant product sales revenue, we expect to incur losses from operations for the near future and will be required to seek additional capital to sustain our operations.

It is anticipated that we will continue to report negative operating cash flow in future periods, likely until one or more of our products generate sufficient revenue to cover our operating expenses. If any of the warrants are exercised, all net proceeds of the warrant exercise will be used for working capital to fund negative operating cash flow.

Our cash balance of \$162,451 will not be sufficient to fund our operations for at least the next 12 months. Additionally, if we are unable to generate sufficient revenues to pay our expenses, we will need to raise additional funds to continue our operations. We have historically financed our operations through private equity and debt financings. Recent economic turmoil and severe lack of liquidity in the debt capital markets together with volatility and rapidly falling prices in the equity capital markets have severely and adversely affected capital raising opportunities. We do not have any commitments for financing at this time, and financing may not be available to us on favorable terms, if at all. If we are unable to obtain debt or equity financing in amounts sufficient to fund our operations, if necessary, we will be forced to suspend or curtail our operations. In that event, current stockholders would likely experience a loss of most or all of their investment. Additional funding that we do obtain may be dilutive to the interests of existing stockholders.

To the extent, we raise additional capital by issuing equity securities or obtaining borrowings convertible into equity, ownership dilution to existing stockholders will result and future investors may be granted rights superior to those of existing stockholders. The incurrence of indebtedness or debt financing would result in increased fixed obligations and could also result in covenants that would restrict our operations. Our ability to obtain additional capital may depend on prevailing economic conditions and financial, business and other factors beyond our control. Economic crisis and disruptions in the U.S. and global financial markets may adversely impact the availability and cost of credit, as well as our ability to raise money in the capital markets. Instability in these market conditions may limit our ability to access the capital necessary to fund and grow our business. The Company cannot provide any assurances that it will be able to raise the additional capital needed to fund its operations, or if the Company is able to raise such additional capital, that any such financing will be on terms which are beneficial to the existing shareholders.

Working Capital

	September 30, 2017	December 31, 2016
Current assets	\$ 402,402	\$ 301,252
Current liabilities	2,259,018	3,648,520
Working Capital Deficit	<u>\$ (1,856,616)</u>	<u>\$ (3,347,268)</u>

Current assets for September 30, 2017 increased compared to December 31, 2016 primarily due to an increase in cash due to the sale of our products and the proceeds from the issuance of common stock.

Current liabilities for September 30, 2017 decreased compared to December 31, 2016 primarily due to a decrease in accounts payable, customer deposits, and derivative liability.

Cash Flows

	Nine Months Ended September 30,	
	2017	2016
Net Cash (Used in) Operating Activities	\$ (339,291)	\$ (698,547)
Net Cash Provided by Financing Activities	463,539	738,619
	<u>\$ 124,248</u>	<u>\$ 40,072</u>

Net Cash Provided by (Used in) Operating Activities

Our primary uses of cash from operating activities include payments to consultants for research and development, compensation and related costs, legal and professional fees, computer and internet expenses and other general corporate expenditures.

Cash used in operating activities consist of net loss adjusted for certain non-cash items, primarily equity-based compensation expense, common stock issued in exchange for services, accretion of debt discount and debt issuance costs on convertible notes and the change in fair value of derivative liabilities due primarily to the mark to market of the Company's derivatives embedded in the convertible notes, and a gain of settlement of liabilities during the nine months ended September 30, 2017, as well as the effect of changes in working capital and other activities.

In addition, the net decrease in cash from changes in working capital activities from the nine months ended September 30, 2016 to the nine months ended June 30, 2017 primarily consisted of a decrease in inventory, a decrease in prepaid expenses and other current assets, an increase in accounts payable and accrued expenses, and an increase in customer deposits.

Net Cash Provided by Financing Activities

For the nine months ended September 30, 2017, financing activities provided cash of \$463,539 which resulted from an increase of \$245,500 in net proceeds from the issuance of common stock, net of issuance costs of \$165,000 in proceeds from note payable-related party. For the nine months ended September 30, 2016, financing activities provided \$738,619 which resulted from an increase of \$490,122 in proceeds from the issuance of convertible notes payable, net of issuance costs and \$271,370 in proceeds from issuance of asset based loans, net of issuance costs.

Going Concern

At September 30, 2017, we had an accumulated deficit of \$28,924,326 and incurred a net loss of \$2,524,873 for the nine months ended September 30, 2017. We expect to incur further losses in the development of our business, all of which casts substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is dependent upon our ability to generate future profitable operations and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS.

Not applicable to smaller reporting companies.

Item 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of our disclosure controls and procedures, as such term is defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this Quarterly Report on Form 10-Q, to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure, and that such information is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Based upon that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are not effective as of September 30, 2017, due to the fact that management has not fully remediated the material weakness described in our Current Report on Form 10-K filed with the Securities and Exchange Commission on April 20, 2017, as amended on April 26, 2017.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the nine months ended September 30, 2017, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

We must maintain effective internal controls to provide reliable financial reports and to detect and prevent fraud. If we cannot provide reliable financial reports or prevent fraud, we may not be able to manage our business as effectively as would be possible with an effective control system in place. We have not performed an in-depth analysis to determine if historical undiscovered failures of internal controls exist, and may in the future discover areas of our internal control that need improvement.

We have been assessing our internal controls to identify areas that need improvement. We are in the process of implementing changes to internal controls, but have not yet completed implementing these changes. Failure to implement these changes to our internal controls or any others that it identifies as necessary to maintain an effective system of internal controls could harm our operating results and cause investors to lose confidence in our reported financial information. Any such loss of confidence would have a negative effect on the trading price of our common stock.

For the year ended December 31, 2016, we and our independent registered public accounting firm identified a material weakness in our internal control over financial reporting due to the Company not maintaining a sufficient complement of personnel with an appropriate level of accounting knowledge and experience in the application of accounting for warrants to purchase common and preferred stock issued in connection with convertible notes payable and convertible preferred stock and accounting for non-employee stock options. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. If the Company does not address the material weaknesses, we may not be able to manage our business as effectively as would be possible with an effective control system in place.

PART II. OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

We are currently not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries' officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.. Any of these situations could have a material adverse effect on our business.

Item 1A. RISK FACTORS

We believe there are no changes that constitute material changes from the risk factors previously disclosed in our Annual Report on Form 10-K, filed with the SEC on April 20, 2017, as amended on April 26, 2017.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the nine months ended September 30, 2017, we issued shares of our common stock that were not registered under the Securities Act, and were not previously disclosed in a Current Report on Form 8-K as follows:

On June 16, 2017, the Company issued 500,000 shares to a vendor that were valued at \$3,950 for the settlement of an outstanding accounts payable balance of \$4,870. The company recorded a gain on settlement of debt of \$920.

On February 17, 2017, the Company issued 67,000,000 shares of the Company's common stock to Libre Design, LLC in exchange for services at a fair value of \$73,700.

On March 22, 2017, the Company issued 2,000,000 shares of the Company's common stock to a vendor in exchange for services at a fair value of \$2,600.

On June 15, 2017, the Company issued 75,000,000 shares of the Company's common stock to a vendor in exchange for services at a fair value of \$397,500.

On March 16, 2017, the Company entered into a securities purchase agreement ("SPA") with TLG, Inc, and TRD, Inc. ("Investors") pursuant to which the Company agreed to sell 25,000,000 restricted shares of the Company's common stock, in an above market transaction at a purchase price of \$0.004 per share for a total of \$100,000. On May 1, 2017, the Company entered into an amendment to the TLG, Inc SPA. The modification allowed TLG, Inc to purchase an additional 25,000,000 of restricted shares of the Company's common stock at a purchase price of \$0.006 per share for a total of \$150,000. TLG exercised all of these options on May 2, 2017.

From March 16, 2017 through November 8, 2017, the Company has issued, in reliance upon Section 4(a)(2) of the Securities Act, 14,699,616 shares of common stock at a weighted average price per share of \$0.0025 pursuant to conversion notices of convertible promissory notes outstanding totaling approximately \$36,749. The shares were issued to a total of one lender. The issuance of such convertible promissory notes was previously disclosed in the Company's periodic reports filed with the Securities and Exchange Commission. As of November 8, 2017, the remaining principle balance owed by the Company pursuant to a convertible promissory note is \$0.

The shares identified in this Part II, Item 2 were not registered under the Securities Act. The shares qualified for exemption under Section 4(a)(2) of the Securities Act since the issuance of the shares by us did not involve a public offering. The offering was not a "public offering" as defined in Section 4(a)(2) due to the insubstantial number of persons involved in the deal, size of the offering, manner of the offering and number of securities offered. We did not undertake an offering in which we sold a high number of securities to a high number of investors. Based on an analysis of the above factors, we have met the requirements to qualify for exemption under Section 4(a)(2) of the Securities Act.

Item 3. DEFAULTS UPON SENIOR SECURITIES

There has been no default in the payment of principal, interest, sinking or purchase fund installment, or any other material default, with respect to any indebtedness of the Company.

Item 4. MINE SAFETY DISCLOSURES

None.

Item 5. OTHER INFORMATION

None.

Item 6. EXHIBITS

Exhibit Number	Description of Exhibit
31.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1+	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Schema
101.CAL	XBRL Taxonomy Calculation Linkbase
101.DEF	XBRL Taxonomy Definition Linkbase
101.LAB	XBRL Taxonomy Label Linkbase
101.PRE	XBRL Taxonomy Presentation Linkbase

+ In accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MyDx, Inc.

Date: November 14, 2017

By: /s/ Daniel R. Yazbeck

Name: Daniel R. Yazbeck

Title: Chief Executive Officer and Chief Financial Officer

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND
CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Daniel R. Yazbeck, certify that;

1. I have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2017 of MyDx, Inc. (the “registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15 (f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2017

By: /s/ Daniel R. Yazbeck
Name: Daniel R. Yazbeck
Title: Chief Executive Officer and
Chief Financial Officer

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND
CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly Report of MyDx, Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2017 filed with the Securities and Exchange Commission (the "Report"), I, Daniel R. Yazbeck, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented.

Date: November 14, 2017

By: /s/ Daniel R. Yazbeck
Name: Daniel R. Yazbeck
Title: Chief Executive Officer and
Chief Financial Officer

This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.